Publications by authors named "P R Kowey"
Background: Decisions about stroke prevention strategies in atrial fibrillation (AF) typically balance thromboembolism reduction against increased bleeding from oral anticoagulation therapy (OAC). When determining eligibility for OAC, guidelines recommend calculation of thromboembolic event rates using a validated score such as CHA2DS2-VASc. In contrast, routine calculation of bleeding scores is not recommended, in part because many patient factors associated with an increased risk of bleeding are associated with an even larger increased risk of ischemic stroke.
View Article and Find Full Text PDFArticle Synopsis
- Left bundle branch area pacing (LBBAP) is a new approach to pacing that aims to improve heart function after aortic valve replacement, compared to the traditional right ventricular septal pacing (RVSP).
- The Left Bundle BRAVE study is a clinical trial designed to compare LBBAP and RVSP in patients with severe aortic stenosis and high-degree heart block to see which method better preserves heart function.
- Key outcomes being measured in the study include changes in heart strain and ejection fraction, along with other markers of heart health and patient performance over a 9-month period.
Background: Practice guidelines recommend ablation (ABL) in atrial fibrillation (AF) for rhythm control. Guidance for antiarrhythmic drugs (AADs) post-ABL is limited.
Objective: The purpose of this study was to determine AAD and ABL practices in the United States and Europe.
Article Synopsis
- Direct oral anticoagulants are commonly used for preventing strokes in patients with atrial fibrillation and flutter, but concerns about bleeding limit their use; milvexian is a new drug that might work as well with less bleeding risk.
- The LIBREXIA AF trial is a large global study comparing milvexian to apixaban, enrolling 15,500 participants to assess if milvexian can prevent strokes without increasing bleeding events significantly.
- The results from this study aim to clarify the efficacy and safety of milvexian compared to apixaban over a projected 4-year follow-up period.